Skip to main content
User Image

Shaun Sabico

Associate Professor

Associate Professor and Deputy Director

كلية العلوم
Chair for Biomarkers of Chronic Diseases, Biochemistry Department, College of Science, KSU
publication
Journal Article
2025

Burdens of type 2 diabetes and cardiovascular disease attributable to sugar-sweetened beverages in 184 countries

The consumption of sugar-sweetened beverages (SSBs) is associated with type 2 diabetes (T2D) and cardiovascular diseases (CVD). However, an updated and comprehensive assessment of the global burden attributable to SSBs remains scarce. Here we estimated SSB-attributable T2D and CVD burdens across 184 countries in 1990 and 2020 globally, regionally and nationally, incorporating data from the Global Dietary Database, jointly stratified by age, sex, educational attainment and urbanicity. In 2020, 2.2 million (95% uncertainty interval 2.0-2.3) new T2D cases and 1.2 million (95% uncertainty interval 1.1-1.3) new CVD cases were attributable to SSBs worldwide, representing 9.8% and 3.1%, respectively, of all incident cases. Globally, proportional SSB-attributable burdens were higher among men versus women, younger versus older adults, higher- versus lower-educated adults, and adults in urban versus rural areas. By world region, the highest SSB-attributable percentage burdens were in Latin America and the Caribbean (T2D: 24.4%; CVD: 11.3%) and sub-Saharan Africa (T2D: 21.5%; CVD: 10.5%). From 1990 to 2020, the largest proportional increases in SSB-attributable incident T2D and CVD cases were in sub-Saharan Africa (+8.8% and +4.4%, respectively). Our study highlights the countries and subpopulations most affected by cardiometabolic disease associated with SSB consumption, assisting in shaping effective policies and interventions to reduce these burdens globally.

Publisher Name
Springer
Magazine \ Newspaper
Nature Medicine
more of publication
publications

Background

by Wani K, Kumar B, Amer OE, Al-Daghri NM, Sabico S
2025
Published in:
Springer Nature
publications

Background: Fibroblast growth factor-21 (FGF21) and omentin-1 have been recognized as potent antidiabetic agents with potential hepatoprotective activity.

by Alenazi MM, Sabico S, Alnaami AM, Wani K, Hussain SD, Al-Daghri NM
2025
Published in:
Springer Nature
publications

This study investigates the 10-year atherosclerotic cardiovascular disease (ASCVD) risk in different metabolic obesity phenotypes in Saudi adults. A cohort of 5460 adults (aged 40-79) was…

by Wani K, Kumar B, Al-Daghri NM, Sabico S
2025
Published in:
Wiley